PoPulation Pharmacokinetics of abacavir in infants, toddlers and children
introduction
Abacavir is a potent nucleoside reverse transcriptase inhibitor (NRTI), prescribed in combination with other antiretroviral agents (nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs)) for the treatment of human immunodeficiency virus (HIV) infection in both paediatric and adult patients (1, 2) . It is marketed for paediatric patients from 3 months to 16 years at the dose of 8 mg/ kg twice daily, up to a maximum of 300 mg twice daily.
Abacavir is well absorbed following oral administration and distributed into body tissues, including the central nervous system. It is extensively metabolized by the liver and less than 2% is excreted as unchanged drug in the urine. The two major catabolic pathways include oxidation by alcohol dehydrogenase (ADH) and conjugation by uridine diphosphate glucuronyltransferase (UGT), resulting in inactive carboxylate and glucuronide metabolites (3, 4) . The antiviral activity of abacavir results from its intracellular activation to carbovir triphosphate (CBV-TP). CBV-TP competes with the endogenous nucleotide 2'-deoxyguanosine triphosphate (dGTP) for incorporation into the nucleic acid chain and terminates the DNA chain by preventing addition of new bases (5) . The endpoint for efficacy, as indicated by the change from baseline in viral load (plasma HIV-1 RNA) and T cells count rise was significantly correlated with area under the concentration-time curve (AUC) (6) . The AUC 0-12 value of 6.02 mg•h/L was set as target exposure both in adults and children (7) .
The pharmacokinetics of abacavir has been previously investigated in children (8) (9) (10) (11) (12) (13) (14) (15) . However these studies were based on either a small number of patients, sparse sampling or narrow age range of the children, which renders difficult the assessment of the role of developmental factors on drug disposition. Accurate characterisation of these factors may allow not only further assessment of the individual dosing requirements across different age groups, but also insight into processes determining maturation and metabolic capacity, which may be deemed drug-independent. In this investigation, we make use of a model-based approach to analyse three different studies in children across a wide age range, with the objective of obtaining more reliable prediction of pharmacokinetic profiles in individual patients. In addition, given the availability of tablet and solution dosage forms, this analysis offered us the opportunity to explore the potential influence of formulation on paediatric pharmacokinetic parameters.
methods clinical trials
The data were obtained from three studies: PENTA (Pediatric European Network for the Treatment of AIDS) 13, PENTA 15 and a pharmacokinetic sub-study within the main ARROW (AntiRetroviral Research fOr Watoto) trial (8) (9) (10) . Briefly, the primary objectives of these studies were to compare the pharmacokinetics of once daily versus twice daily of abacavir and lamivudine in HIV type-1-infected children. The European studies PENTA 13 and PENTA 15 were conducted in children aged from 2-13 years and from 3 months-3 years, respectively. The ARROW pharmacokinetic sub-study was conducted in Uganda with children aged 3-12 years. In total, sixty-nine children were included in this population pharmacokinetic meta-analysis. The mean (SD) age was 5.74 (3.40) (range 0.42 -12.84) years and the mean (SD) weight was 18.7 (8.0) (range 7.6 -60.9) kg. Pharmacokinetic samples were obtained at steady-state at time T0 (immediately before administration) and T1, T2, T3, T4, T6, T8 and T12 h after administration for the twice daily regimen and an additional sample at T24 h for the once daily regimen. A summary of trial design, dosage regimens, and patient characteristics are presented in Table 1 
Pharmacokinetic modelling
Pharmacokinetic analysis was carried out using the nonlinear mixed effects modelling program NONMEM v6 (V2.0; Icon Development Solutions, USA) (16) . First order conditional estimation (FOCE) method with interaction option was used to estimate pharmacokinetic parameters and their variability.
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Inter-individual variability of the pharmacokinetic parameters was estimated using an exponential model and could be expressed as follows:
where θ i represents the parameter value of the i th subject, θ TV the typical value of the parameter in the population and η i the variability between subjects which is assumed to follow a normal distribution with a mean of zero and variance ω 2 .
Covariate analysis followed a forward and backward selection process. The stepwise covariate modelling (17, 18) Clinical application in therapeutic drug monitoring The feasibility of a model-based approach in therapeutic drug monitoring was evaluated by considering two main scenarios in which pooled population data and sparse pharmacokinetic sampling are used as basis for predicting drug exposure in new patients:
1. To assess model performance in new patients, 10 children were randomly removed from the original dataset. The parameters for the remaining 59 children were re-estimated. The model parameters were then used to predict individually the pharmacokinetics of the 10 children excluded from the analysis, taking into account the effect of covariates in each patient. Predictions were compared to the observed data graphically by means of visual predictive check plots (1000 simulations/patient).
2. To assess the impact of empirical sparse sampling on model predictions, data from new patients using only three samples (T0, T1 and T3) were added in a stepwise manner to the dataset (i.e., initial population, n=59). Model parameters were then re-estimated for all 60 children (of which 59 had frequent sampling scheme). The new model was used to predict the full pharmacokinetic profile of single patients with sparse samples. Results were compared graphically with the original data using visual predictive check plots (1000 simulations/patient). This approach was selected as an initial step to the use of a full Bayesian analysis, in which model parameter values from a historical population (instead of the data) are used as priors to anchor the estimation of the parameters of interest for a new subject or population.
results

Population pharmacokinetic modelling
A total of 1065 plasma abacavir concentrations were available for population modelling. Data fitted a two-compartment model with first order absorption and elimination. Inter-individual variability was best described by an exponential model and was then estimated for Q/F, V 1 /F, V 2 /F and CL/F. Inter-occasion variability on CL/F was coupled to inter-individual variability by an additive model, respectively. Residual variability was best described by a proportional model. PoPulation Pharmacokinetics of abacavir in infants, toddlers and children During covariate model building, the inclusion of age, weight and formulation on CL/F, and weight on V 1 /F all separately produced a significant decrease in objective function (OFV). However, following the backward exclusion process, only the effect of weight on CL/F and V 1 /F was found to be significant ((∆OFV >7.88 (p<0.005, c 2 distribution)). Therefore, the influence of weight on CL/F and V 1 /F was retained in the model as follows:
Where 
observed concentration values (DV). Right upper panel shows conditional weighted residuals (CWRES) vs. time (TIME). Left lower panel shows individual predictions (IPRE) vs. observed concentration values (DV). Right lower panel shows conditional weighted residuals (CWRES) vs. population predictions (PRED). Solid line represents the identity line. (b) Normalized Prediction Distribution Errors (NPDE) analysis. Upper panel shows the histogram of the distribution of the NPDE, with the density of the standard Gaussian distribution overlaid. Lower panel shows NPDE versus time (TIME) Figure 2 VPC in infants and toddlers (a), children (b), following once daily (c) and twice daily dosing regimen (d): observed data are plotted using a circle (○). The dashed lines represent the 5 th , and 95 th percentiles of simulated data (n=1000). The solid lines represent the 50 th of simulated data (n=1000).
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Figure 3 Simulated AUC distribution and median (continuous line) and 5 th and 95 th percentiles (dashed lines) of the observed AUC in infants and toddlers (a), in children (b), following once daily dosing (c) and twice daily dosing (d)
PoPulation Pharmacokinetics of abacavir in infants, toddlers and children Moreover, the assessment of the predictive performance of the model included scenarios in which drug exposure was predicted in new patients taking sparse sampling schemes into account. In both cases, estimates of parameter accuracy and precision were acceptable. As shown in figure 4 , accurate predictions can be made of individual patient profiles using this model, despite some evidence of over-estimation of residual variability. 
discussions And conclusions
In the present study, we have shown the use of population pharmacokinetic meta-analysis of abacavir based on data obtained by a rich sampling strategy in 69 children from three pharmacokinetic studies. We believe that pooling of data offers the opportunity to evaluate drug disposition across a wide age and body weight range. Such an evaluation may be essential to assess the suitability of dosing recommendations for children. Even though our analysis is limited to abacavir data, we anticipate that such considerations are necessary and applicable to most if not all compounds for paediatric indications.
From a methodological perspective, meta-analytical concepts are required to ensure thorough understanding of the implications of developmental growth on pharmacokinetics in paediatric patients. Despite attempts to describe changes in drug disposition by allometric models, it should be clear that the paediatric population encompasses a very heterogeneous group of patients. Inferences about pharmacokinetics in individual patients may be challenging with data arising from a very limited number of patients, especially when the objective is to predict individual exposure in prospective patients or to adjust dosing regimens in chronic treatment, as in the case of therapeutic drug monitoring. The scope of population pharmacokinetic modelling is to enable the description and prediction of ADME processes in a parametric manner, so that hierarchical parameters can be derived that can discriminate population from individual patient characteristics. In paediatric pharmacokinetics, however, discrimination between population and individual differences is further confounded by the role of maturation and other factors associated with developmental growth, including changes in metabolic capacity (22) . In a previous work (7), Cella et al have shown that a model-based approach offers a suitable basis for estimation of pharmacokinetic parameters even when only sparse samples may be available. However, such models do not necessarily permit accurate prediction of the differences in pharmacokinetics for individuals whose characteristics are not represented in the population used during model building and validation. As shown in a previous analysis (23) , a model developed using data in older children cannot reliably predict exposure in infants and toddlers, and vice versa. This lack of predictive performance is partly explained by the fact that covariate-parameter correlations may not remain constant beyond the range of observations. Estimation of covariate effects is therefore not sufficient to allow accurate extrapolation of pharmacokinetics from a reference population to another population.
Our results indicate that it is not the overall number of patients that determines the predictive performance of a model, but rather the availability of data from the overall population, so that parameter distributions can be accurately estimated and imputations can be made about individuals belonging to any part of the population with adequate precision. Our results show that good predictive performance of a model can be achieved with a considerably limited number of individuals as long as the covariate distribution in the subjects used for model building represents
PoPulation Pharmacokinetics of abacavir in infants, toddlers and children the covariate distribution in the population described by the model. This is critical to ensure that differences driven by covariates are not captured as random effects, nor random effects are wrongly associated with covariates. This is illustrated by the difference in the magnitude of parameter estimates in our analysis and in estimated parameters from single trials (table 3) . Whereas the focus of previous publications was on the use of modelling as the basis for drug development (i.e., early paediatric trials), little attention has been paid to the implications of similar modelling requirements for accurate dosing adjustment and therapeutic drug monitoring in clinical practice (24, 25) . In the present study, we have assessed the predictive performances of the final model using several simulation scenarios in which potential differences in individual exposure are evaluated. Our results indicated that the final model can accurately predict drug exposure with currently used dosing regimens in new patients, even in case of sparse sampling.
Population pharmacokinetic and/or pharmacodynamic model validation is another key-issue
to consider when models are to be used for simulation purposes (i.e. dosage optimisation or clinical trial simulation). Validation procedures are lacking in many publications reporting the development of population pharmacokinetic and /or pharmacodynamic models (26) . In fact, advanced internal evaluations were performed on merely 16% of the models in children (27) . In 
